Release Standards

Defined Criteria. Controlled Authorization. Disciplined Distribution.

Release Philosophy

At PureLux Bio, material release is not automatic upon receipt or production completion. Release authorization follows structured review procedures designed to confirm documentation continuity, analytical alignment, and labeling integrity prior to distribution.

Release standards exist to support operational discipline within the Research Use Only (RUO) framework. They are applied consistently across product categories and are governed by defined internal criteria rather than demand, timing pressure, or promotional considerations.

Release is a controlled decision — not a default action.

Lot Identification & Intake Review

Upon receipt of production materials, each lot is assigned or verified with a unique lot identifier for internal tracking and traceability purposes.

Intake procedures include documentation review, lot confirmation, and alignment of received materials with associated analytical records where applicable.

Materials are not authorized for distribution until intake documentation and lot traceability standards are satisfied.

Analytical Alignment

Release consideration includes review of analytical findings associated with the evaluated lot sample.

Analytical scope may include identity confirmation, chromatographic purity assessment, quantitative assay review, and additional evaluations as determined appropriate to compound profile.

Analytical documentation is reviewed for consistency, completeness, and alignment with internal release criteria.

Where independent laboratory collaboration has been utilized, associated third-party documentation may be incorporated into the review process.

Release standards apply to evaluated lot samples and corresponding documented production lots. They do not imply unit-level testing of individual containers.

Documentation Integrity Review

Prior to release authorization, documentation undergoes structured internal review to confirm:

Consistency between lot identifiers and analytical records
Alignment between labeling and documentation
Completion of required internal records
Traceability of material through intake and verification stages

Where documentation discrepancies are identified, release may be delayed pending clarification, reconciliation, or additional review. PureLux Bio reserves the right to withhold or delay release if defined documentation standards are not met.

Labeling & Traceability Controls

All distributed materials are labeled with lot identifiers designed to support traceability to internal documentation and associated analytical records.

Labeling review is conducted to confirm accuracy and consistency prior to release.

Traceability systems are structured to support procurement review, documentation continuity, and responsible research handling.

Controlled Distribution Authorization

Release authorization is granted only after internal review standards are satisfied.

Authorization is a deliberate administrative step confirming that documentation, analytical alignment, and labeling standards have been reviewed under the PureLux Bio framework.

Release authorization does not constitute regulatory approval, pharmaceutical certification, clinical validation, or endorsement for any non-research application.

All products remain designated strictly for laboratory Research Use Only.

Ongoing Oversight & Continuous Review

Release standards are subject to periodic review and refinement as part of PureLux Bio’s ongoing operational oversight.

Internal procedures may evolve to strengthen documentation clarity, traceability, and review consistency.

This framework exists to support disciplined distribution within the defined Research Use Only environment — not to imply clinical, therapeutic, or regulatory positioning.